MK-1942 + Placebo
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment Resistant Depression
Conditions
Treatment Resistant Depression
Trial Timeline
May 20, 2021 → Sep 8, 2023
NCT ID
NCT04663321About MK-1942 + Placebo
MK-1942 + Placebo is a phase 2 stage product being developed by Merck for Treatment Resistant Depression. The current trial status is terminated. This product is registered under clinical trial identifier NCT04663321. Target conditions include Treatment Resistant Depression.
What happened to similar drugs?
3 of 20 similar drugs in Treatment Resistant Depression were approved
Approved (3) Terminated (3) Active (14)
🔄HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05602727 | Phase 2 | Terminated |
| NCT04663321 | Phase 2 | Terminated |
Competing Products
20 competing products in Treatment Resistant Depression